The US moves to reclaim the therapeutic pipeline

Today, the Department of Health and Human Services (HHS) announced new plans aimed at restoring American leadership in clinical research by removing unnecessary barriers to clinical trials — in other words, properly doing Clinical Trial Abundance.In a call with journalists, Acting FDA Commissioner Kyle Diamantas and NIH Director Jay Bhattacharya outlined a series of reforms designed to hasten Phase I trials and encourage companies to conduct studies in the US. The FDA's efforts are intended to r...